Pfizer President Albert Bourla announced that PF-07321332 would be ready by the end of 2021, the drug that will allow treating COVID-19 from home.
In that sense, if the Food and Drug Administration (FDA) approves it, the pill could begin to be distributed in the United States as of the end of the year, Bourla said in an interview with CNCB.
Although Pfizer is also working on an injectable form for the drug, it is focusing on developing the oral treatment (that is, in pills) because it is more practical for patients.
“Oral treatment has several advantages, and one of them is that you don’t need to go to the hospital for treatment, as has been the case with injectables so far,” Bourla explained.
It should be remembered that on March 23, in a statement, Pfizer had already announced the start of phase 1 studies for PF-07321332, which it described as a candidate for “protease inhibitor with powerful anti-viral activity against SARS-CoV-2 “. The studies are being done in the United States.
The drug, according to the pharmaceutical company, could also serve against other coronaviruses other than SARS-CoV-2. “That could change the rules of the game,” Bourla said Tuesday.
According to the CEO of Pfizer, the studies of the pill could exceed phase three this year, depending on what the FDA says, the agency that regulates the use of drugs in the United States.
“If everything goes well and we implement it at the same speed that we have done so far, and we are doing it, and if the regulators do the same, and are doing it, I hope the phase 3 studies will be ready by the end of the year. “Bourla explained.